Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2026-01-22 @ 2:25 AM
Study NCT ID:
NCT05672251
Status:
RECRUITING
Last Update Posted:
2025-10-06
First Post:
2023-01-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
City of Hope Medical Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Diffuse Large B-Cell Lymphoma | View |
| None | Recurrent Grade 3b Follicular Lymphoma | View |
| None | Recurrent High Grade B-Cell Lymphoma | View |
| None | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | View |
| None | Recurrent Transformed Chronic Lymphocytic Leukemia | View |
| None | Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell … | View |
| None | Refractory Diffuse Large B-Cell Lymphoma | View |
| None | Refractory Grade 3b Follicular Lymphoma | View |
| None | Refractory High Grade B-Cell Lymphoma | View |
| None | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | View |
| None | Refractory Transformed Chronic Lymphocytic Leukemia | View |
| None | Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell … | View |
Keywords: